Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

16 Jan 2009 08:31

RNS Number : 7610L
ViaLogy PLC
16 January 2009
 



VIALOGY PLC ("VIALOGY" OR "THE COMPANY")

VIALOGY AND ATASCOSA EXTEND OIL PROJECT; SIGN COMMERCIAL CONTRACT

Friday, January 16, 2009LondonEngland. Vialogy PLC (LSE: VIY) announces today it has signed a contract with Atascosa Exploration LLC to analyze data from three separate oil prospects in south central Texas, known collectively as the Galba Unit. The analysis will determine size and boundaries of reservoirs, overall porosity maps, and optimal well locations. Using its patented QuantumRD™ processing, that exploits subtle variations in geoseismic noise to overcome limitations in current seismic data processing techniques, Vialogy will provide locations for between 6 to 9 wells at sites the companies estimate will be needed to produce the recoverable oil in place

The three prospects include both currently producing areas and new, undeveloped areas. According to Atascosa's geological and engineering estimates, these prospects potentially contain over a million barrels of oil recoverable. ViaLogy's responsibilities include overseeing new, high-resolution 3D seismic surveys, an integrated reservoir assessment, and maintaining reservoir models during the project's life cycle. The first well is planned for completion by Q1 2009. 

This expanded project replaces a previously announced single pilot well, and will accelerate QuantumRD's proof-of-concept across multiple wells in three different formations, achieving one of the company's key business objectives. In addition, the new technology promises to address a problem faced by the oil industry worldwide - drilling dry holes. In Texas itself, 4 out of 10 exploratory wells, including those drilled with the aid of seismic, fail to find gas or oil in economically producible quantities. Such abortive attempts are costly. According to US Dept. of Energy (DOE) Energy Information Administration (EIA) statistics, the 2006 average cost for drilling an on-shore dry hole in the US was over $450,000. 

Under the Atascosa contract, Vialogy will receive for its drill site analysis an interest in production. Atascosa and Vialogy have agreed on 5% of the working interest (WI) back-in after pay-out (BIAPO) to Vialogy in the first well on each prospect. That is, once all well development costs have been paid out, ViaLogy receives 5% of the working interest revenues going forward minus operating expenses. For subsequent wells on each of the three Galba Unit prospects, ViaLogy will receive a right to participate at cost for 5% of the working interest. 

Going forward, the companies have agreed to implement a pricing model for the QuantumRD service based on both a drill site analysis fee and an interest in the prospect. For this contracted project, once drilling is completed, an estimate of the total dollar value of ViaLogy's projected revenues will be possible.

Atascosa CEO, John Mullins, commented, "We have introduced QuantumRD into our critical decision path for determining well location. We believe the unique formation and porosity assessments can deliver revenue growth, and save on production expense. If we prove conclusively that by using the technology we can reduce the number of dry holes, I believe it will have a major impact on the industry." 

Vialogy CEO, Robert W. Dean, said: "We are delighted that Atascosa has decided to extend the use of QuantumRD into a broader exploration and production setting that will best show the capability of this technology, provide revenue, and justify a business model that Vialogy can carry forward."

In anticipation of a successful outcome ViaLogy is making plans to market QuantumRD extensively. 

ViaLogy

Robert W Dean, President & CEO - US (+1 703-589-3807) Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 

Atascosa Exploration LLC John D. Mullins, CEO (+1 210-402-3656) 

Nominated Advisor (Seymour Pierce) Mark Percy +44 (0) 20-7107-8000 

Brokers to ViaLogy PLC 

St. Helen's Capital +44 (0) 7628 5582

About ViaLogy: Network Centric Signal Processing ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTGUUUWGUPBURQ
Date   Source Headline
1st Apr 201912:12 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSYourgene raises IONA® test awareness in Egypt
26th Feb 20193:21 pmRNSHolding(s) in Company
22nd Feb 201910:00 amEQSHardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020
22nd Feb 20198:05 amRNSHolding(s) in Company
19th Feb 20192:21 pmRNSHolding(s) in Company
19th Feb 20197:15 amEQSHardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked
18th Feb 201910:59 amRNSIssue of Equity
18th Feb 20197:00 amRNSMajor Capital & Commercial Restructuring
8th Jan 20197:00 amRNSYourgene launches Sage 32 plex
3rd Dec 20187:00 amRNSHalf-year Results
7th Nov 20187:00 amRNSChange of Name to Yourgene Health plc
5th Nov 201811:24 amRNSShare Transfer
2nd Nov 20187:00 amRNSDirectorate Change
25th Oct 20183:30 pmRNSResult of AGM
25th Oct 20187:00 amRNSHolding(s) in Company
25th Oct 20187:00 amRNSAGM Statement
22nd Oct 20187:00 amRNSFurther re: Fundraise
12th Oct 20181:15 pmRNSAvailability of Research Commentary
12th Oct 20187:00 amRNSTrading Update and Notice of Results
5th Oct 20187:00 amRNSDirector's dealing and share option issue
4th Oct 20187:00 amRNS$1 million collaboration agreement
3rd Oct 20187:00 amRNSDirectorate change
2nd Oct 20187:00 amRNSNotice of AGM
1st Oct 201812:20 pmRNSResult of Fundraise
28th Sep 20185:41 pmRNSProposed fundraise to raise approximately £2.5m
28th Sep 20185:40 pmRNSFull year results and half-year trading update
25th Sep 201811:31 amRNSHolding(s) in Company
21st Sep 20184:10 pmRNSHolding(s) in Company
21st Sep 20187:00 amRNSHolding(s) in Company
20th Sep 20189:30 amRNSSenior Appointment & Anticipated Director Change
19th Sep 201811:05 amRNSSecond Price Monitoring Extn
19th Sep 201811:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSLegal Settlement & Licence Agreement with Illumina
11th Sep 20187:00 amRNSHolding(s) in Company
7th Aug 201810:57 amRNSHolding(s) in Company
12th Jul 20187:00 amRNSShare option awards
4th Jul 20187:00 amRNSBoard Changes
26th Jun 20181:31 pmRNSCollaboration with Abnova
13th Jun 20187:00 amRNSOutstanding NIPS Solution Provider Award Win
11th Jun 20187:00 amRNSDNA sequencing technology development agreement
7th Jun 20183:44 pmRNSHolding(s) in Company
5th Jun 20187:00 amRNSPremaitha signs partnership agreement in India
4th Jun 201811:05 amRNSHolding(s) in Company
24th May 20187:00 amRNSHolding(s) in Company
18th May 20184:38 pmRNSHolding(s) in Company
18th May 201812:06 pmRNSHolding(s) in Company
18th May 201812:05 pmRNSHolding(s) in Company
18th May 20189:40 amRNSHoldings in Company
15th May 20187:00 amRNSPremaitha expands footprint with new laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.